Adaptive Profiling (APL) and other biochip companies aim to harness the power of microsystems technology together with advances in chemistry and molecular biology, to become service and technology providers to organizations involved in pharmaceutical research and development. By supplying a unique range of decisionmaking tools that aid an earlier identification of qualified drug candidates for clinical development, the company should gain a significant share of the US$10 billion biological screening, bioavailability and toxicity assessment market.
Conference Article| August 01 2002
Miniaturized screening technologies for drug discovery
J. M. Cooper;
- Views Icon Views
- Share Icon Share
J. M. Cooper, A. E. G. Cass; Miniaturized screening technologies for drug discovery. Biochem Soc Trans 1 August 2002; 30 (4): 802–806. doi: https://doi.org/10.1042/bst0300802
Download citation file: